Recent Company News

• 08:01 AM ET Jul 21, 2025
  

  FDA grants 510(k) clearance for Takeda's HyHub, HyHub Duo

• 08:04 AM ET Jul 17, 2025
  

  Keros Therapeutics announces first patient dosed in phase 3 RENEW trial of elritercept in MDS ($14.49, 0.00)

• 09:18 AM ET Jul 14, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 03:08 AM ET Jul 14, 2025
  

  Takeda Pharmaceutical's TAK-861 meets all primary and secondary endpoints in two phase 3 studies in narcolepsy type 1 (¥4361.0000, 0)

• 03:04 AM ET Jul 02, 2025
  

  JCR Pharmaceuticals enrolls participants in JR-141 global phase III clinical trial (¥503.0000, 0)

• 10:11 AM ET Jun 30, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (130 total)

• 08:06 AM ET Jun 30, 2025
  

  Takeda Pharmaceutical obtains US FDA approval for GAMMAGARD LIQUID ERC (¥4425.0000, 0)

• 07:39 PM ET Jun 15, 2025
  

  Ascentage Pharma notes encouraging data of Olverembatinib in Ph+ ALL reported at EHA (HK$62.35, 0.00)

• 08:44 AM ET Jun 10, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:31 PM ET Jun 09, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market